Categories: CancerHealthcareNews

SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference

BOSTON and ROLLE, Switzerland, Aug. 28, 2024 /PRNewswire/ — SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen FutureHealth Conference in early September.

Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 22nd Annual Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024, at 1:50 p.m. EDT.

The following week, co-Founder and Chief Executive Officer, Dr. Jurgi Camblong, will join a Panel Discussion on AI in Healthcare at the 9th Annual TD Cowen FutureHealth Conference in New York City on Tuesday, September 10, 2024, at 3:15 p.m. EDT.

The presentations will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-present-at-the-22nd-annual-morgan-stanley-healthcare-conference-and-9th-annual-td-cowen-futurehealth-conference-302233232.html

SOURCE SOPHiA GENETICS

Staff

Recent Posts

CGTN: In the wake of tragedy, Hong Kong comes together to rebuild

BEIJING, Dec. 8, 2025 /PRNewswire/ -- CGTN published an article on the post-disaster rescue and…

6 hours ago

The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts”

New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before…

6 hours ago

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)…

9 hours ago

Rapid Dose Completes Extension to Promissory Notes

Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the…

10 hours ago

LifeScan Successfully Emerges from Financial Restructuring Process, Enters Next Chapter with Renewed Strength

Eliminates More Than 75% of Prepetition Debt, Positioning Company to Improve Product Affordability and Availability…

12 hours ago

LifeScan Successfully Emerges from Financial Restructuring Process, Enters Next Chapter with Renewed Strength

Eliminates More Than 75% of Prepetition Debt, Positioning Company to Improve Product Affordability and Availability…

12 hours ago